• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $HSCS

    HeartSciences Inc.

    Subscribe to $HSCS
    $HSCS
    Industrial Specialties
    Health Care

    IPO Year: 2022

    Exchange: NASDAQ

    Recent Analyst Ratings for HeartSciences Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    HeartSciences Inc. SEC Filings

    See more
    • HeartSciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - HeartSciences Inc. (0001468492) (Filer)

      3/21/25 5:15:07 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HeartSciences Inc. (0001468492) (Filer)

      3/13/25 4:16:43 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by HeartSciences Inc.

      10-Q - HeartSciences Inc. (0001468492) (Filer)

      3/13/25 4:03:27 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 253G2 filed by HeartSciences Inc.

      253G2 - HeartSciences Inc. (0001468492) (Filer)

      3/11/25 8:30:26 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form QUALIF filed by HeartSciences Inc.

      QUALIF - HeartSciences Inc. (0001468492) (Filer)

      3/11/25 12:15:04 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 1-A filed by HeartSciences Inc.

      1-A - HeartSciences Inc. (0001468492) (Filer)

      2/12/25 4:15:14 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

      8-K - HeartSciences Inc. (0001468492) (Filer)

      1/21/25 4:33:57 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form RW filed by HeartSciences Inc.

      RW - HeartSciences Inc. (0001468492) (Filer)

      12/19/24 5:00:02 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Inc. filed SEC Form 8-K: Other Events

      8-K - HeartSciences Inc. (0001468492) (Filer)

      12/17/24 5:05:07 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form RW filed by HeartSciences Inc.

      RW - HeartSciences Inc. (0001468492) (Filer)

      12/17/24 5:00:27 PM ET
      $HSCS
      Industrial Specialties
      Health Care

    HeartSciences Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Heart Test Laboratories Inc.

      SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)

      12/11/23 8:30:12 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Heart Test Laboratories Inc.

      SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)

      11/27/23 4:02:41 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form SC 13D filed by Heart Test Laboratories Inc.

      SC 13D - Heart Test Laboratories, Inc. (0001468492) (Subject)

      6/14/23 5:06:17 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form SC 13D filed by Heart Test Laboratories Inc.

      SC 13D - Heart Test Laboratories, Inc. (0001468492) (Subject)

      6/14/23 5:04:28 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Heart Test Laboratories Inc.

      SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)

      3/10/23 4:54:57 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Heart Test Laboratories Inc.

      SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)

      3/10/23 4:54:22 PM ET
      $HSCS
      Industrial Specialties
      Health Care

    HeartSciences Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    HeartSciences Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 4 filed by Director Bent Bruce

      4 - HeartSciences Inc. (0001468492) (Issuer)

      1/23/25 4:30:07 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Officer Hilz Mark T

      4 - HeartSciences Inc. (0001468492) (Issuer)

      1/21/25 7:21:18 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Wells David R.

      4 - HeartSciences Inc. (0001468492) (Issuer)

      1/21/25 5:17:26 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Officer Watson Danielle

      4 - HeartSciences Inc. (0001468492) (Issuer)

      1/21/25 5:17:06 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Szymczak Brian

      4 - HeartSciences Inc. (0001468492) (Issuer)

      1/21/25 5:16:44 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Officer Simpson Andrew

      4 - HeartSciences Inc. (0001468492) (Issuer)

      1/21/25 5:16:22 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • Officer Simpson Andrew acquired 17 shares, increasing direct ownership by 0.22% to 7,629 units (SEC Form 4)

      4 - Heart Test Laboratories, Inc. (0001468492) (Issuer)

      8/14/24 5:57:51 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Simpson Andrew

      4 - Heart Test Laboratories, Inc. (0001468492) (Issuer)

      3/22/23 7:57:24 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Wells David R.

      4 - Heart Test Laboratories, Inc. (0001468492) (Issuer)

      3/22/23 7:56:39 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Szymczak Brian

      4 - Heart Test Laboratories, Inc. (0001468492) (Issuer)

      3/22/23 7:56:46 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson

      Southlake, TX, May 08, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it will host a live investor webinar on Wednesday, May 14, 2025, at 2:00 p.m. EDT | 11:00 a.m. PDT, featuring a presentation and Q&A session with CEO Andrew Simpson. Register Now To attend the webinar and participate in the live Q&A, please register through: HeartSciences Investor Webinar May 14th at 2:00 pm EDT This is an opportunity for investors to gain insight into HeartSciences' missi

      5/8/25 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

      Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Girish Nadkarni, MD, Dr. Joshua Lampert, MD, and Dr. Akhil Vaid, MBBS, to its Scientific Advisory Board. These appointments underscore HeartSciences' commitment to advancing and transforming data-driven AI-ECG technology. "We are honored to welcome Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid to our Scientific Advisory Board," said Andrew Simpson, CEO of HeartScien

      5/7/25 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program

      Southlake, TX, May 01, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has launched the MyoVista InsightsTM platform and related early adopter program for select reference sites. MyoVista Insights is a cloud-native next-generation ECG Management System designed to enhance both clinical decision-making and healthcare IT efficiency. It will integrate company developed and third-party AI-ECG algorithms as part of future releases and the current platform off

      5/1/25 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results

      Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2025 ended January 31, 2025 and provided a business update. Third Fiscal Quarter 2025 Highlights: During the third quarter of fiscal year 2025 ("Q3 FY2025") and to date in 2025, HeartSciences has seen material progress towards FDA submissions of our products and there have been significant positive developments in the AI-ECG field. A summary of

      3/13/25 4:15:00 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications

      Southlake, TX, March 10, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has engaged Integrous Communications, a premier investor relations firm, to enhance communication channels with investors and the investment community. Under the expert guidance of Integrous Communications, HeartSciences will embark on a comprehensive investor relations program, benefiting from Integrous Communications' proven track record in collaborating with leading medical compa

      3/10/25 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

      Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2025 ended October 31, 2024 and provided a business update. Second Fiscal Quarter 2025 Highlights: In the run up to the close of 2024 and the second quarter of fiscal year 2025 ("Q2 FY2025"), HeartSciences saw across the board material progress and more positive developments for the field of AI-ECG, its MyoVista® wavECGTM device, MyoVista® Insigh

      12/16/24 4:15:00 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

      Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment APC 5734. This approval would allow outpatient settings to receive reimbursement for HeartSciences' MyoVista® wavECGTM algorithm and MyoVista® InsightsTM low ejection fraction algorithm

      11/13/24 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

      Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that Company CEO Andrew Simpson has been invited to participate in the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC and hosted by M-Vest, from Tuesday October 15 to Thursday October 17, 2024. Mr. Simpson is scheduled to participate in a fireside chat with analyst Allen Klee at 10:30 a.m. Eastern Time on Thursday, October 17th.

      10/14/24 4:15:00 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

      Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the first quarter fiscal 2025 ended July 31, 2024 and provided a business update. First Fiscal Quarter 2025 Highlights: During the first quarter of fiscal year 2025 ("Q1 FY2025"), HeartSciences has seen material progress for both its MyoVista wavECGTM device, MyoVista InsightsTM cloud-platform and associated first cl

      9/12/24 4:15:00 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

      Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the close of a non-dilutive financing, with $1.9 million in net proceeds.  The unsecured loan note has an 18-month maturity date and follows the recent 12-month extension of a $500,000 loan note to September 2025. Andrew Simpson, CEO of HeartSciences, said, "We have extended our capital runway by $2.4 million since late August ahead of our upcoming FDA subm

      9/12/24 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care

    HeartSciences Inc. Leadership Updates

    Live Leadership Updates

    See more
    • HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

      Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Girish Nadkarni, MD, Dr. Joshua Lampert, MD, and Dr. Akhil Vaid, MBBS, to its Scientific Advisory Board. These appointments underscore HeartSciences' commitment to advancing and transforming data-driven AI-ECG technology. "We are honored to welcome Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid to our Scientific Advisory Board," said Andrew Simpson, CEO of HeartScien

      5/7/25 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Adds Key Advisor to its Scientific Advisory Board

      Southlake, TX, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Partho P. Sengupta, MD, MBBS, FACC, to its Scientific Advisory Board. "Dr. Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company's technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board," said Andrew Simpson, CEO of HeartSciences. "Dr. Sengupta has

      2/26/24 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Expands its Scientific Advisory Board

      Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board. "Dr. Strom has been assisting us in recent interactions with the FDA and we are delighted to welcome him to our Scientific Advisory Board as we prepare for FDA submission of our MyoVista device and cloud platform, in addition to algorithms licensed from the Icahn School of Medi

      2/12/24 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Appoints New Scientific Advisory Board Member

      Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board. "We are delighted to welcome Dr. Glicksberg, an elite data scientist and an instrumental leader in the establishment of the AI-ECG program at the Icahn School of Medicine at Mount Sinai, New York (Mount Sinai) to HeartSciences' Scientific Advisory Board," said Andrew Simpson, CEO

      2/1/24 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Signs Distribution Agreement with FJ Medical, Denmark

      Southlake, TX, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has signed a distribution agreement with FJ Medical, Denmark. FJ Medical has been appointed as HeartSciences' distributor for the MyoVista® wavECGTM  and related supplies for the Nordic countries of Denmark, Sweden, Norway and Finland. FJ Medical has more than 23 years of experience selling cardiac imaging and screening equipment in the Nordic region and i

      8/31/23 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results

      Southlake, Texas, July 19, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today provided a business update and reported financial results for the fiscal year ended April 30, 2023. Key milestones during Fiscal 2023 and to date: Completed patient enrollment for the MyoVista® wavECGTM multi-center pivotal study; on track for FDA submission later in the year;Further expansion of the IP portfolio in the US and internationally, bringing the total number

      7/19/23 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care

    HeartSciences Inc. Financials

    Live finance-specific insights

    See more
    • HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments

      Entered into Transformative Agreements with Icahn Mount Sinai Filed FDA Pre-Submission Request to Change to 510(k) Submission from De Novo following Issuance of New Classification for AI ECG by FDA To host conference call on Wednesday, October 25, 2023 Southlake, TX, Oct. 19, 2023 (GLOBE NEWSWIRE) --  Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced a conference call to update investors on recent key achievements and positive developments. The conference call will be host

      10/19/23 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care